Statement of Need

Postpartum depression (PPD) is one of the most common morbidities related to childbirth, affecting 13-19% of women. However, only 35% of women with PPD are identified in the clinic despite guideline recommendations calling for screening with a validated assessment tool at several time points in the perinatal period. Of patients identified with PPD, only 25.8% ultimately receive treatment, resulting in negative consequences for the mother, baby, and family. PPD has historically been treated with non-specific antidepressants, but there is limited evidence on the efficacy and safety of antidepressants for PPD, and their slow onset of action leads to suboptimal treatment outcomes. Advances in understanding of the pathophysiology of PPD have led to the recent approval of novel neurosteroid therapeutics for the treatment of PPD. Thus, there is a need to increase screening of perinatal women to improve outcomes and ensure therapeutic interventions are initiated earlier.

Target Audience

This activity is intended for OB/GYNs, maternal fetal medicine physicians, psychiatrists, APPs and nurses who manage patients with or at-risk of postpartum depression.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Introduce system-based strategies to increase screening for peripartum depression
• Interpret the most up-to-date clinical trial data surrounding novel neurosteroids for the treatment of postpartum depression (PPD)
• Develop frameworks to reduce the median time to optimal and equitable treatment in women with PPD

Method of Participation

To receive credit, learners are required to complete a baseline assessment; design, develop, and implement an action plan using our automated platform; view the online interventions; and return after 30 days to report on their progress in making system-level changes. A thorough response to the reflection questionnaire on your involvement in the quality improvement activity is also required for meaningful participation. A certificate will be available upon completion of the reflection questionnaire. There is no fee to participate in the activity or for the generation of the certificate.

ABIM credit will be submitted to ABIM within 30 days of completion.

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Accreditation and Credit Designation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The American College of Osteopathic Obstetricians and Gynecologists is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this Internet Enduring Material for a maximum of 3.5 AMA PRA Category 1 Credit(s)^™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Physician assistants (PAs) and nurse practitioners (NPs) may participate in this educational activity and earn a certificate of completion as AAPA and AANP accept AMA PRA Category 1 Credits^™ through their reciprocity agreements.

Rush University Medical Center designates this Internet Enduring Material for a maximum of 3.5 ANCC contact hour(s).

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

By providing your ABIM Diplomate number and date of birth, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS each month.

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

The American College of Osteopathic Obstetricians and Gynecologists designates this program for a maximum of 3.5 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.

This activity qualifies as a Component IV OCC activity for the American Osteopathic Board of Obstetrics and Gynecology. Record of completion is maintained by the American College of Osteopathic Obstetricians and Gynecologists.

Disclosures

It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education (ICPE) to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.

The following financial relationships have been provided:

Melisa Biskup Lott, DO
Advisory Board Member: Natera, Inc.

Jessica Boudos, PA-C
No financial relationships to disclose.

Kristina M. Deligiannidis, MD
Research Grant: Gerbera Therapeutics, Premier Healthcare, Sage Therapeutics, Woebot Health
Consultant: Biogen, Brii Biosciences, Gerbera Therapeutics, GH Research, Neuroscience Software, Reunion Neuroscience,
Sage Therapeutics

Marianne Corrieri-Alaniz, BSN
No financial relationships to disclose.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: SSRI/SNRI antidepressants not approved for PPD

Staff and Reviewer Disclosures

Staff members from Rush University Medical Center and the Office of Interprofessional Continuing Education, the American College of Osteopathic Obstetricians and Gynecologists, the Academy for Continued Healthcare Learning (ACHL), and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACOOG, Rush University Medical Center, and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.

Acknowledgement

This educational activity is presented in collaboration with the American College of Osteopathic Obstetricians and Gynecologists, Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Sage Therapeutics, Inc